Vitestro, a Dutch company founded in 2017, received De Novo authorization from the U.S. Food and Drug Administration this month for Aletta. Aletta is the first robotic device cleared specifically to perform blood draws autonomously.
How the system works
Aletta combines multiple sensors and algorithms: near‑infrared light maps the arm, ultrasound scans search for veins, and a computer vision model trained on annotated ultrasound images selects the target vein and guides the needle. The device is intended to operate under human supervision, with one experienced phlebotomist able to oversee multiple units.
Clinical performance
In clinical trials, Aletta achieved a 95% first‑stick success rate, a 0.6% haemolysis rate, and a median draw time of 1 minute 49 seconds. Vitestro reports that a single phlebotomist can supervise three devices simultaneously.
Practical implications — workforce and institutional impact
Blood draws are among the most common procedures in medicine. According to the information in the source, the United States employs about 140,000 phlebotomists and has roughly 18,000 openings per year. Attrition in the profession often outpaces replacement. Because Aletta does not tire, does not leave shifts, and — per the source — does not miss veins more often on darker skin tones, the system could reduce reliance on human labor for routine blood collection.
Regulation and competition
Developing the device required eight years of clinical trials. The FDA’s De Novo authorization also establishes a regulatory precedent that other companies can follow when seeking clearance for similar devices.
Conclusion
Aletta is designed to perform one very common medical task — blood draws — autonomously. The reported clinical results show high first‑stick success and short draw times; FDA clearance may accelerate adoption of comparable solutions and address staffing shortages in phlebotomy.
